Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
November 21, 2023 18:32 ET
|
Mesoblast Limited
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and...
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
October 30, 2023 20:04 ET
|
Mesoblast Limited
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
September 26, 2023 06:18 ET
|
Mesoblast Limited
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent...
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
September 21, 2023 03:30 ET
|
Mesoblast Limited
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path...
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
August 30, 2023 19:07 ET
|
Mesoblast Limited
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
Mesoblast Financial Results and Corporate Update Webcast
August 29, 2023 07:00 ET
|
Mesoblast Limited
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
August 03, 2023 20:10 ET
|
Mesoblast Limited
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the US Food and...
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
July 30, 2023 20:31 ET
|
Mesoblast Limited
NEW YORK, July 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
June 04, 2023 20:21 ET
|
Mesoblast Limited
NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has...
Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
May 25, 2023 19:28 ET
|
Mesoblast Limited
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...